Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
Ultragenyx Pharmaceutical (RARE) Stock Price & Analysis
396 Followers
RARE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$33.36 - $68.68
Previous Close$51.82
Volume176.00
Average Volume (3M)662.40K
Market Cap
$3.64B
Enterprise Value$3.04B
Total Cash (Recent Filing)$629.35M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-5.1
Beta0.87
Next Earnings
Aug 03, 2023EPS Estimate
-$2.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.26
Shares Outstanding70,814,462
10 Day Avg. Volume600,991
30 Day Avg. Volume662,398
Standard Deviation0.15
R-Squared0.10
Alpha-0.00284
Financial Highlights & Ratios
Price to Book (P/B)-450.29
Price to Sales (P/S)36.52
Price to Cash Flow (P/CF)-5.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.92
Enterprise Value/Gross Profit9.49
Enterprise Value/Ebitda-4.26
Forecast
1Y Price Target
$90.73Price Target Upside76.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Ultragenyx Pharmaceutical News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RARE FAQ
What was Ultragenyx Pharmaceutical’s price range in the past 12 months?
Ultragenyx Pharmaceutical lowest stock price was $33.36 and its highest was $68.68 in the past 12 months.
What is Ultragenyx Pharmaceutical’s market cap?
Currently, no data Available
When is Ultragenyx Pharmaceutical’s upcoming earnings report date?
Ultragenyx Pharmaceutical’s upcoming earnings report date is Aug 03, 2023 which is in 56 days.
How were Ultragenyx Pharmaceutical’s earnings last quarter?
Ultragenyx Pharmaceutical released its earnings results on May 04, 2023. The company reported -$2.33 earnings per share for the quarter, missing the consensus estimate of -$1.992 by -$0.338.
Is Ultragenyx Pharmaceutical overvalued?
According to Wall Street analysts Ultragenyx Pharmaceutical’s price is currently Undervalued.
Does Ultragenyx Pharmaceutical pay dividends?
Ultragenyx Pharmaceutical does not currently pay dividends.
What is Ultragenyx Pharmaceutical’s EPS estimate?
Ultragenyx Pharmaceutical’s EPS estimate is -$2.07.
How many shares outstanding does Ultragenyx Pharmaceutical have?
Ultragenyx Pharmaceutical has 70,814,460 shares outstanding.
What happened to Ultragenyx Pharmaceutical’s price movement after its last earnings report?
Ultragenyx Pharmaceutical reported an EPS of -$2.33 in its last earnings report, missing expectations of -$1.992. Following the earnings report the stock price went up 3.078%.
Which hedge fund is a major shareholder of Ultragenyx Pharmaceutical?
Among the largest hedge funds holding Ultragenyx Pharmaceutical’s share is Baker Bros Advisors LP. It holds Ultragenyx Pharmaceutical’s shares valued at 19M.
---
Ultragenyx Pharmaceutical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$90.73 (76.43% Upside)
$90.73 (76.43% Upside)
Blogger Sentiment
Bullish
RARE Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 51.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 2.4%
Last 30 Days ▲ 2.4%
News Sentiment
Positive
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.19%
12-Months-Change
Fundamentals
Return on Equity
-141.42%
Trailing 12-Months
Asset Growth
-0.05%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.
---
Top 5 ETFs holding RARE
Vanguard Health Care ETF
$10.17M
iShares Russell 1000 Growth ETF
$8.57M
iShares Core S&P Total U.S. Stock Market ETF
$3.65M
iShares Russell 1000 ETF
$2.58M
iShares U.S. Healthcare ETF
$2.12M
Up to five ETFs with an Outperform Smart Score that hold RARE. The ETFs are listed according to market value of RARE within the ETF
---
---